NASOPHARYNGEAL CARCINOMA: MODERN APPROACHES TO DIAGNOSIS AND TREATMENT
Keywords:
nasopharyngeal carcinoma, head and neck cancer, radiotherapy, chemoradiotherapy, immunotherapy, Epstein–Barr virus.Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor of the head and neck region characterized by distinct epidemiological, morphological, and clinical features. The disease demonstrates high radiosensitivity, early lymphatic metastasis, and a strong association with Epstein–Barr virus (EBV) infection. This article reviews current concepts of etiology, pathogenesis, morphology, diagnosis, and treatment strategies for nasopharyngeal carcinoma. Particular attention is given to combined and personalized therapeutic approaches.
References
NCCN Clinical Practice Guidelines in Oncology.
Head and Neck Cancers. Version 2024.
National Comprehensive Cancer Network, 2024.
Forastiere A. A., Trotti A., Pfister D. G., Grandis J. R.
Head and neck cancer: recent advances and new standards of care.
Journal of Clinical Oncology. 2018;36(7):720–730.
Chen Y. P., Chan A. T. C., Le Q. T., Blanchard P., Sun Y., Ma J.
Nasopharyngeal carcinoma.
The Lancet. 2019;394(10192):64–80.
Lee A. W. M., Ng W. T., Chan L. L. K.
Evolution of treatment for nasopharyngeal cancer: success and setback in the intensity-modulated radiotherapy era.
Radiotherapy and Oncology. 2014;110(3):377–384.
Zhang L., Huang Y., Hong S., et al.
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma.
Journal of Clinical Oncology. 2016;34(12):1412–1418.
Ribassin-Majed L., Marguet S., Lee A., et al.
What is the best treatment of locally advanced nasopharyngeal carcinoma?
Annals of Oncology. 2017;28(9):2268–2276.
Bray F., Laversanne M., Sung H., et al.
Global cancer statistics 2024.
CA: A Cancer Journal for Clinicians. 2024;74:1–35.
World Health Organization.
WHO Classification of Head and Neck Tumours. 5th ed.
Lyon: IARC Press, 2023.
